HBPCF
Helix BioPharma Corp.·Healthcare
1.73
0.000%(+0.00)
Market OpenLast Updated: — ET
52W L: $0.4552W H: $1.73
HBPCF NEWS
thenewswire.com
Mar 16
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and six-month periods ended January 31, 2026 (the “Financial Statements” ), the management's discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). All values are in Canadian dollars unless stated otherwise. “While our current financial position reflects a challenging capital markets environment for small-cap biotech companies, our focus remains firmly on securing the financing necessary to advance Helix into its next phase,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “The Management and Board are actively pursuing financing opportunities aimed at securing approximately twelve months of operating runway, which will allow the Company to pursue its near-term objectives, including listing on a U.S. securities exchange. While there is still work to be done, we have reason to be cautiously optimistic as we intensify these efforts and expect to communicate further on our roadmap to achieve this goal soon.”
thenewswire.com
Feb 24
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Toronto, Ontario – TheNewswire - February 24, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company presented new data yesterday on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16 th Annual World ADC London conference, held in London, United Kingdom. The presentation, titled “Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies” , was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference's opening day. Dr. Davis was selected to present as part of the conference's Seminar Day program, which brings together leading ADC experts to address key challenges and opportunities in next-generation conjugate design, safety, combination strategies, and regulatory development. His participation underscores Helix's growing leadership in the development of innovative ADC technologies. The World ADC London conference continues over the following two days with a comprehensive scientific program covering advances in ADC discovery, development, and clinical translation.
thenewswire.com
Feb 5
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
(Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the extension of its Research and Exclusive Option Agreement (the “Agreement” ) with metaShape Pharma AG ( “metaShape” ) covering LEUMUNA™ through December 31, 2028. The Agreement was originally entered into in April 2023 between metaShape and Laevoroc Immunology AG, providing metaShape with an exclusive research license and an option to negotiate a commercial license for LEUMUNA within the field of adipose tissue-related and metabolic diseases. Referred to internally at metaShape as “MS 001”, the compound is being developed as an orally administered, first-in-class co-therapy to GLP-1 receptor agonists, such as semaglutide, aimed at improving the selectivity of adipose tissue reduction and the durability of weight loss.
thenewswire.com
Jan 30
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Toronto, Ontario – TheNewswire - 30 January, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC: “HBPCF” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the voting results from the Annual General and Special Meeting of its Shareholders (the “ Meeting ”) held on Friday, January 30, 2026. A total of 61,885,815 common shares were voted at the Meeting, representing 81.03 % of Helix's total issued and outstanding shares. Shareholders voted overwhelmingly in favor of all items of business before the Meeting. The four director nominees listed in Helix's Management Information Circular (the “Information Circular” ) dated December 15, 2025, were re-elected as directors of the Company to hold office for the ensuing year or until their successors are elected or appointed. The detailed results of the vote for each director are set out below:
